Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study
- Resource Type
- Article
- Source
- In
Vaccine 20 October 2023 41(44):6558-6564 - Subject
- Language
- ISSN
- 0264-410X